£6m funding for pioneering medical specialist

David Budd, genedrive chief executive
AIM-listed near patient molecular diagnostics company, genedrive, has raised £6m in funding from new and existing equity investors through the issue of equity, loan notes and a broker option. The funding includes a £3.5m cornerstone investment from BGF, the UK’s most active investor in growing businesses. Based in Manchester, genedrive has developed the first portable device to diagnose the Hepatitis C virus, based on detecting the virus’s genetic code. By removing the need for diagnosis to take place in large hospital ... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...